Abstract | BACKGROUND: METHODS: We tested for the first time the antitumor effects on gastric cancer cells of Erb-hcAb, a novel fully human compact antibody, prepared in our laboratory, which targets a different epitope of ErbB2 with respect to trastuzumab, the only anti-ErbB2 antibody currently in clinical use for both breast and gastric cancer therapy. RESULTS: Herein we demonstrate that the in vitro and in vivo growth of gastric cancer cells is efficiently inhibited by Erb-hcAb, which shows antitumor effects on the NCI-N87 cell line more potent than those observed for trastuzumab. CONCLUSIONS:
Erb-hcAb could be a promising candidate in the immunotherapy of gastric cancer as it combines the antiproliferative effect associated with the inhibition of ErbB2 signaling on tumor target cells with the ability to induce antibody-dependent cellular cytotoxicity.
|
Authors | Carmine Fedele, Silvia Carvalho, Gennaro Riccio, Rolando Paciello, Paolo Laccetti, Fernando Schmitt, Claudia De Lorenzo |
Journal | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
(Gastric Cancer)
Vol. 17
Issue 1
Pg. 107-15
(Jan 2014)
ISSN: 1436-3305 [Electronic] Japan |
PMID | 23460348
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Erb-hcAb
- Immunoconjugates
- ERBB2 protein, human
- Receptor, ErbB-2
- Trastuzumab
|
Topics |
- Animals
- Antibodies, Monoclonal, Humanized
(pharmacology)
- Antineoplastic Agents
(pharmacology)
- Cell Death
(drug effects)
- Cell Line, Tumor
- Cell Movement
(drug effects)
- Cell Proliferation
(drug effects)
- Female
- Humans
- Immunoconjugates
(pharmacology)
- Mice
- Mice, Inbred BALB C
- Molecular Targeted Therapy
(methods)
- Receptor, ErbB-2
(immunology, metabolism)
- Signal Transduction
(drug effects)
- Stomach Neoplasms
(drug therapy, metabolism, pathology)
- Trastuzumab
- Xenograft Model Antitumor Assays
|